Adjusted risk of composite outcome and cerebrovascular event associated with dabigatran non-persistence
| Variable | HR (95% CI) | p Value | HR (95% CI) | p Value |
| Composite outcome | Cerebrovascular event | |||
| Dabigatran non-persistence | 1.76 (1.60 to 1.94) | <0.0001 | 3.75 (2.59 to 5.43) | <0.0001 |
| Age (per year increase) | 1.08 (1.07 to 1.09) | <0.0001 | 1.05 (1.3 to 1.08) | <0.001 |
| Sex (reference female) | 1.18 (1.07 to 1.30) | <0.01 | 0.45 (0.30 to 0.66) | <0.0001 |
| Rural residence (vs urban) | 1.08 (0.94 to 1.24) | 0.31 | 1.31 (0.81 to 2.11) | 0.27 |
| University education | 0.92 (0.78 to 1.10) | 0.38 | 0.66 (0.32 to 1.36) | 0.26 |
| Most responsible MD Internist (reference generalist) | 0.97 (0.87 to 1.08) | 0.55 | 0.93 (0.63 to 1.38) | 0.72 |
| Most responsible MD cardiologist (reference generalist) | 0.87 (0.76 to 1.00) | 0.04 | 0.74 (0.44 to 1.26) | 0.27 |
| Hypertension | 0.90 (0.81 to 1.00) | 0.05 | 1.20 (0.82 to 1.74) | 0.35 |
| Coronary artery disease | 1.03 (0.93 to 1.15) | 0.54 | 0.97 (0.65 to 1.44) | 0.87 |
| Heart failure | 1.50 (1.35 to 1.65) | <0.0001 | 0.93 (0.63 to 1.37) | 0.70 |
| Diabetes | 1.16 (1.04 to 1.29) | <0.01 | 1.05 (0.69 to 1.61) | 0.81 |
| Cerebrovascular disease | 1.19 (1.04 to 1.35) | 0.01 | 1.71 (1.12 to 2.60) | 0.01 |
| Bleeding history | 0.93 (0.81 to 1.07) | 0.33 | 1.19 (0.71 to 1.99) | 0.50 |
| Depression | 1.10 (0.97 to 1.25) | 0.15 | 1.02 (0.62 to 1.70) | 0.93 |
| Prior warfarin use | 1.05 (0.95 to 1.16) | 0.35 | 1.29 (0.89 to 1.87) | 0.17 |
| Concomitant medications | 1.05 (1.04 to 1.06) | 0.0001 | 0.99 (0.95 to 1.03) | 0.48 |
| Number of treating physicians | 1.02 (1.01 to 1.02) | <0.0001 | 1.00 (0.99 to 1.02) | 0.73 |
| Length of stay at AF admission (per day increase) | 1.01 (1.00 to 1.01) | <0.001 | 0.98 (0.95 to 1.01) | 0.16 |
| Time since first AF diagnosis (per year increase) | 0.99 (0.98 to 1.01) | 0.25 | 0.95 (0.91 to 1.00) | 0.07 |
AF, atrial fibrillation; MD, physician; TIA, transient ischaemic attack.